Postoperative pain

Stage (next event)

Expected Date

NDA Acceptance

June 2021 (Est)

Catalyst Info & Data Links

Mechanism of Action


  • Long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of postoperative pain.

  • Bupivacaine blocks the firing of local pain receptors at the surgical site, while meloxicam works in synergy to reduce local inflammation at the surgical site. 

  • Combining both modalities in a long-acting, locally applied formulation may offer enhanced pain relief for patients relative to currently marketed interventions for postoperative pain, while at the same time reducing the dependence on opioid pain medications.

  • Click here to read more


  • MARCAINE (bupivacaine, marketed by Hospira, Inc.) and generic forms of bupivacaine

  • NAROPIN (ropivacaine, marketed by Fresenius Kabi USA, LLC) and generic forms of ropivacaine

  • EXPAREL ® (bupivacaine liposome injectable suspension, marketed by Pacira Pharmaceuticals, Inc.)

  • ON-Q Avanos post-surgical pumps


  • +30M annual U.S. surgical procedures requiring postoperative pain management

  • Source: 2020 Heron Therapeutics Leerink Update (slide 12)

Updated by HC

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Amp Mid-Q1 '19 Update

HRTX Mid-Q1 '19 Update

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon